Io Biotech, INC

IO Biotech, Inc. has ceased operations and filed a voluntary petition for Chapter 7 bankruptcy, leading to the resignation of its board and termination of all employees.

IO Biotech, Inc. received a Nasdaq notice for failing to meet the minimum $50 million market value of listed securities requirement.

IO Biotech announced a significant workforce reduction and engaged Raymond James as a financial advisor to explore strategic alternatives.

IO Biotech announced it is exploring strategic alternatives, including a potential merger, sale of assets, or liquidation, to maximize stockholder value.

IO Biotech, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, initiating a 180-day compliance period.

IO Biotech, Inc. announced the resignation of its Senior Vice President and Chief Accounting Officer, Brian Burkavage, and the appointment of Chief Financial Officer Amy Sullivan to the role.

IO Biotech reports substantial doubt about its ability to continue as a going concern, following the FDA's recommendation against a BLA submission for its lead cancer vaccine, Cylembio, despite promising Phase 3 PFS data.

IO Biotech reports increased losses and a going concern warning, as its lead cancer vaccine Cylembio narrowly missed statistical significance in a pivotal Phase 3 melanoma trial.

IO Biotech, a clinical-stage biopharmaceutical company, announces its Q1 2025 financial results and provides an update on the progress of its Phase 3 trial for Cylembio in advanced melanoma.

IO Biotech's Q3 2024 report details financial results and provides updates on its clinical programs, including the Phase 3 trial for IO102-IO103.

IO Biotech, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results and provided an update on its clinical development programs, including its Phase 3 trial for IO102-IO103.

IO Biotech's first quarter 2024 results show a net loss of $19.5 million, with ongoing clinical trial progress for their cancer vaccine candidates.

IO Biotech's 10-K filing highlights the company's progress in clinical trials, particularly the Phase 3 trial for Cylembio, and its ongoing development of novel cancer vaccines.

IO Biotech filed an amendment to its annual report to include the missing signature of the Principal Accounting Officer, with no changes to the financial statements or other disclosures.

IO Biotech's 10-K filing provides a detailed overview of its capital stock, governance, and regulatory compliance, highlighting key aspects for investors.

IO Biotech, Inc. Director David V. Smith was granted 35,144 stock options with an exercise price of $1.50, vesting on June 5, 2026.

IO Biotech, Inc. Director Heidi Hunter was granted 35,144 stock options with an exercise price of $1.50, vesting on June 5, 2026.

IO Biotech, Inc. Director Peter Hirth was granted 35,144 stock options with an exercise price of $1.50, vesting in June 2026.

IO Biotech, Inc. Director Kathleen Sereda Glaub has been granted 35,144 stock options with an exercise price of $1.50, which are set to vest on June 5, 2026.

IO Biotech, Inc. Director Christian E. Elling was granted 35,144 stock options with an exercise price of $1.50, vesting on June 5, 2026.

IO Biotech, Inc. Director Helen Louise Collins was granted 35,144 stock options with an exercise price of $1.50, aligning her interests with the company's long-term performance.

IO Biotech, Inc. announces its 2025 Annual Meeting and provides information on how stockholders can access proxy materials and vote.

IO Biotech announces its 2025 annual meeting of stockholders to be held virtually on June 5, 2025, featuring proposals for director election and auditor ratification.

IO Biotech will hold its annual stockholders meeting on June 6, 2024, to elect directors and ratify the appointment of its accounting firm.

IO Biotech announces its 2024 annual meeting of stockholders to be held virtually on June 6, 2024, featuring proposals for director elections and auditor ratification.

IO Biotech, Inc. has ceased operations and filed for Chapter 7 bankruptcy, initiating the liquidation of its assets.

Novo Holdings A/S has significantly reduced its stake in IO Biotech, Inc., selling over 2.5 million shares and ceasing to be a beneficial owner of more than five percent.

Novo Holdings A/S has reduced its beneficial ownership in IO Biotech, Inc. to approximately 7.3% after selling 841,996 shares in a block trade.

Jorey Chernett has filed an exit statement confirming the disposal of all beneficial ownership in IO Biotech, Inc.

HBM Healthcare Investments (Cayman) Ltd. filed an amendment disclosing a reduction in its beneficial ownership of IO Biotech, Inc. common stock to 3.3%.

Jorey Chernett has reported a beneficial ownership of 6.31% of IO Biotech, Inc.'s common stock, holding 4,543,532 shares.

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have jointly reported a 5.6% beneficial ownership stake in IO Biotech, Inc.

Vivo Capital entities have filed an amended Schedule 13G, reporting their beneficial ownership in IO Biotech, Inc. has fallen below the 5% threshold.

Jorey Chernett has reported a beneficial ownership of 5.3% of IO Biotech, Inc.'s common stock, totaling 3,477,162 shares.